2022-07-05-世界卫生组织-Immunization_Trinidad_and_Tobago_2022_country_profile_18页_387kb

Immunization Coverage Estimates for Trinidad and Tobago (2000-2021)

Summary

WHO and UNICEF estimates national immunization coverage based on reported data, survey estimates, and administrative data, with varying confidence levels.

Key Points

1. Data and Methodology:

   • Estimates are country-specific.
   • Where no data are available, interpolation uses other doses or disease epidemiology.
   • Data sources include government reports and household surveys.
   • No empirical data exist for some recent pre-2015 vaccines like Hib3, HepB3, RotaC.
   • Estimated coverage levels rely primarily on government-reported administrative data.
   • Coverage estimates are challenged ('D-') when they contradict data from D, R, or S sources.
   • A Grade of Confidence (GoC) indicates the quality of supporting data.
   • The 2000 National Multiple Indicator Cluster Survey and 2006 preliminary report provided survey-based confirmation data for several vaccines but was limited to specific age cohorts and vaccine confidence groups.
   • High-grade confidence ('•••') was only achieved when supported by reported data ([R+]), an independent denominator ([D+]), and a supporting survey ([S+]) within 2 years.

2. Vaccine-Specific Overview & Challenges:

   • BCG: No data estimates available, government estimates persistent but unreliability unknown ('•').
   • DTP1: High confidence estimates range from 93-99%. Regularly challenged ('D-'), often lacks survey confirmation ('NA'). Stockouts noted in 2017, 2018, 2016.
   • DTP3: High confidence estimates range from 93-100%. Consistently challenged ('D-'). No survey confirmation in recent years ('NA').
   • Pol3: High confidence estimates range from 94-100%. Mostly challenged ('D-'). Stockouts noted in 2015, 2016.
   • IPV1: Introduced in 2015. Initial estimate (2015) was 6%. From 2016 onwards, estimates range from 90-99%. 2015-2016 estimates highly challenged (R- or D-), some >100% reported. Used to help end Type 2 OPV withdrawal.
   • MCV1: High confidence estimates range from 90-99%. Consistently challenged ('D-'). Stockouts noted in 2016, 2015.
   • MCV2: High confidence estimates range from 83-93%. Mostly challenged ('D-') or challenge noted (D-R-). Draws coverage from MCV1 estimates. Stockout noted in 2016, 2015.
   • RotaC: No empirical data estimate available. 'No accepted empirical data' GoC from 2015. Estimates unavailable for recent years.
   • HepB1: No data estimate available. HepB birth dose coverage estimates not produced according to protocol.
   • HepB3: High confidence estimates range from 92-97%. Consistently challenged ('D-').
   • Hib3: High confidence estimates range from 80-97%. Most estimates challenged ('D-'), except peak 2012 estimate (GoC ••). Est. no empirical data 2010-2014.
   • YFV: High confidence estimates range from 88-98%. Mostly challenged ('D-') or challenge noted (D-R-). Stockouts noted in 2016, 2015.

3. Survey Data Confirmation:

   • The 2000 National Multiple Indicator Cluster Survey provided some manual and reported data confirmation for historical estimates (approx. 2000).
   • No recent (2016-2021) nationally representative household surveys within the last 5 years were used to confirm most estimates for 2010 onwards.

Main Challenges

• Lack of independently verified survey data for most recent years.
• Persistent reports of stockouts ('stock-out') which impact program delivery and coverage accuracy.
• Challenges to estimates based on potentially unreliable reported data ('D-').